RUNX1 and neuroblastoma: In addition, mining of public datasets (GSE49710) showed that RUNX1 levels were negatively correlated with MYCN amplification (P < 0.0001), progression (P < 0.0001), and advanced stage (P = 0.0014, Fig. 1c) by International Neuroblastoma Staging System (INSS).